Protocol feasibility based on current individual patient data: detailed, complete and without geographic limitations.
All data is collected specifically for your protocol.
Standardised feedback from peer-to-peer discussions with the investigators providing the patient data.
LEARN MORE ABOUT THE PROCESS BEHIND OUR
Evidence-based Feasibility
Most patient studies do not complete on schedule, nor within budget :
​
​​​​​
86%​​
of clinical trials fail to
recruit to expected
timelines
​​​​
69%​​
of Phase III protocols require at least one substantial amendment
(average: 3.3)
​​​​
3 months​​
needed at least to
implement a single
Phase III amendment
Data and analyses with a level of detail that is not otherwise available
Precise quantification of the available pool of patients
Assessment of the study’s attractiveness & likely consent in different geographies
LEARN MORE ABOUT OUR IMPACT IN
Paediatrics
Accurate information on what type and size of study is feasible
Regulator-ready reports to negotiate your paediatric study commitment
​​​​​
$1.7m​​
on average in direct costs
per month to run a
Phase III clinical trial
(up to $7m)
​​​​​
$15m​​
on average in unrealised
drug sales for each
month of delay
(up to $245m)
